Last 12 months
Inside the activity.
0 purchase rows · 2 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 1 |
| Dec 2025 | 0 | 1 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 03, 2024 Filed Jun 5, 2024 20:05 UTC |
Wright Richard M.SR. VP & CCO
|
Exercise / conversionCommon Stock | 18,375 | $22.48 | $413,070.00 |
DisclosureSEC source: 0001415889-24-015543 · form4-06052024_080641.xml · nonDerivative · entry 3 Wright Richard M. · CIK 0001646423 · SR. VP & CCO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,677 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 20:05 UTC |
Wright Richard M.SR. VP & CCO
|
Exercise / conversionCommon Stock | 28,469 | $28.00 | $797,132.00 |
DisclosureSEC source: 0001415889-24-015543 · form4-06052024_080641.xml · nonDerivative · entry 2 Wright Richard M. · CIK 0001646423 · SR. VP & CCO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,302 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 20:05 UTC |
Wright Richard M.SR. VP & CCO
|
Exercise / conversionCommon Stock | 20,625 | $2.78 | $57,337.50 |
DisclosureSEC source: 0001415889-24-015543 · form4-06052024_080641.xml · nonDerivative · entry 1 Wright Richard M. · CIK 0001646423 · SR. VP & CCO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,833 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 20:04 UTC |
Jimenez Freddy A.SVP & GENERAL COUNSEL
|
Exercise / conversionIncentive Stock Option (Right to Buy) · Derivative | 8,006 | $0.00 Strike: $10.38 | $0.00 |
DisclosureSEC source: 0001415889-24-015542 · form4-06052024_080652.xml · derivative · entry 3 Jimenez Freddy A. · CIK 0001838114 · SVP & GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,994 Underlying: Common Stock · 8,006 shares Expires 2030-06-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 25% vested on June 18, 2021 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 20:04 UTC |
Jimenez Freddy A.SVP & GENERAL COUNSEL
|
SaleCommon Stock | 8,006 | $33.60 | $269,002.40 |
DisclosureSEC source: 0001415889-24-015542 · form4-06052024_080652.xml · nonDerivative · entry 2 Jimenez Freddy A. · CIK 0001838114 · SVP & GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,924 Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 20:04 UTC |
Jimenez Freddy A.SVP & GENERAL COUNSEL
|
Exercise / conversionCommon Stock | 8,006 | $10.38 | $83,102.28 |
DisclosureSEC source: 0001415889-24-015542 · form4-06052024_080652.xml · nonDerivative · entry 1 Jimenez Freddy A. · CIK 0001838114 · SVP & GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,930 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 30, 2024 Filed Jun 3, 2024 20:06 UTC |
Heath-Chiozzi MargoSVP OF REGULATORY AFFAIRS
|
Exercise / conversionIncentive Stock Option (Right to Buy) · Derivative | 2,608 | $0.00 Strike: $10.38 | $0.00 |
DisclosureSEC source: 0001415889-24-015148 · form4-06032024_080622.xml · derivative · entry 7 Heath-Chiozzi Margo · CIK 0001718112 · SVP OF REGULATORY AFFAIRS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,392 Underlying: Common Stock · 2,608 shares Expires 2030-06-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 25% vested on June 18, 2021 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
| May 30, 2024 Filed Jun 3, 2024 20:06 UTC |
Heath-Chiozzi MargoSVP OF REGULATORY AFFAIRS
|
Exercise / conversionIncentive Stock Option (Right to Buy) · Derivative | 2,043 | $0.00 Strike: $9.02 | $0.00 |
DisclosureSEC source: 0001415889-24-015148 · form4-06032024_080622.xml · derivative · entry 6 Heath-Chiozzi Margo · CIK 0001718112 · SVP OF REGULATORY AFFAIRS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,289 Underlying: Common Stock · 2,043 shares Expires 2028-06-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: As of June 13, 2022, the option is fully vested. Read SEC document |
| May 30, 2024 Filed Jun 3, 2024 20:06 UTC |
Heath-Chiozzi MargoSVP OF REGULATORY AFFAIRS
|
Exercise / conversionIncentive Stock Option (Right to Buy) · Derivative | 29,068 | $0.00 Strike: $2.78 | $0.00 |
DisclosureSEC source: 0001415889-24-015148 · form4-06032024_080622.xml · derivative · entry 5 Heath-Chiozzi Margo · CIK 0001718112 · SVP OF REGULATORY AFFAIRS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,732 Underlying: Common Stock · 29,068 shares Expires 2029-06-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: As of June 19, 2023, the option is fully vested. Read SEC document |
| May 30, 2024 Filed Jun 3, 2024 20:06 UTC |
Heath-Chiozzi MargoSVP OF REGULATORY AFFAIRS
|
SaleCommon Stock | 38,719 | $34.07 | $1,319,156.33 |
DisclosureSEC source: 0001415889-24-015148 · form4-06032024_080622.xml · nonDerivative · entry 4 Heath-Chiozzi Margo · CIK 0001718112 · SVP OF REGULATORY AFFAIRS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,094 F2 · kind: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.850 to $34.445 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. F2 · shares: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.850 to $34.445 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.850 to $34.445 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| May 30, 2024 Filed Jun 3, 2024 20:06 UTC |
Heath-Chiozzi MargoSVP OF REGULATORY AFFAIRS
|
Exercise / conversionCommon Stock | 2,608 | $10.38 | $27,071.04 |
DisclosureSEC source: 0001415889-24-015148 · form4-06032024_080622.xml · nonDerivative · entry 3 Heath-Chiozzi Margo · CIK 0001718112 · SVP OF REGULATORY AFFAIRS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,813 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 30, 2024 Filed Jun 3, 2024 20:06 UTC |
Heath-Chiozzi MargoSVP OF REGULATORY AFFAIRS
|
Exercise / conversionCommon Stock | 2,043 | $9.02 | $18,420.71 |
DisclosureSEC source: 0001415889-24-015148 · form4-06032024_080622.xml · nonDerivative · entry 2 Heath-Chiozzi Margo · CIK 0001718112 · SVP OF REGULATORY AFFAIRS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,205 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 30, 2024 Filed Jun 3, 2024 20:06 UTC |
Heath-Chiozzi MargoSVP OF REGULATORY AFFAIRS
|
Exercise / conversionCommon Stock | 29,068 | $2.78 | $80,809.04 |
DisclosureSEC source: 0001415889-24-015148 · form4-06032024_080622.xml · nonDerivative · entry 1 Heath-Chiozzi Margo · CIK 0001718112 · SVP OF REGULATORY AFFAIRS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,162 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 847 shares of common stock acquired under the Celldex Therapeutics, Inc. 2004 Employee Stock Purchase Plan. Read SEC document |
| May 30, 2024 Filed Jun 3, 2024 20:05 UTC |
Martin Samuel BatesSVP AND CFO
|
Exercise / conversionIncentive Stock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $10.38 | $0.00 |
DisclosureSEC source: 0001415889-24-015147 · form4-06032024_080645.xml · derivative · entry 3 Martin Samuel Bates · CIK 0001709024 · SVP AND CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,600 Underlying: Common Stock · 25,000 shares Expires 2030-06-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 25% vested on June 18, 2021 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
| May 30, 2024 Filed Jun 3, 2024 20:05 UTC |
Martin Samuel BatesSVP AND CFO
|
SaleCommon Stock | 35,000 | $34.05 | $1,191,774.50 |
DisclosureSEC source: 0001415889-24-015147 · form4-06032024_080645.xml · nonDerivative · entry 2 Martin Samuel Bates · CIK 0001709024 · SVP AND CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,128 F1 · kind: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.69 to $34.55 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. F1 · shares: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.69 to $34.55 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.69 to $34.55 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| May 30, 2024 Filed Jun 3, 2024 20:05 UTC |
Martin Samuel BatesSVP AND CFO
|
Exercise / conversionCommon Stock | 25,000 | $10.38 | $259,500.00 |
DisclosureSEC source: 0001415889-24-015147 · form4-06032024_080645.xml · nonDerivative · entry 1 Martin Samuel Bates · CIK 0001709024 · SVP AND CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,128 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 30, 2024 Filed Jun 3, 2024 20:04 UTC |
Cavanaugh SarahSVP OF CORP AFFAIRS & ADMIN.
|
Exercise / conversionIncentive Stock Option (Right to Buy) · Derivative | 10,103 | $0.00 Strike: $9.02 | $0.00 |
DisclosureSEC source: 0001415889-24-015138 · form4-06032024_080652.xml · derivative · entry 5 Cavanaugh Sarah · CIK 0001709113 · SVP OF CORP AFFAIRS & ADMIN. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,103 shares Expires 2028-06-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: As of June 13, 2022, the option is fully vested. Read SEC document |
| May 30, 2024 Filed Jun 3, 2024 20:04 UTC |
Cavanaugh SarahSVP OF CORP AFFAIRS & ADMIN.
|
Exercise / conversionIncentive Stock Option (Right to Buy) · Derivative | 10,750 | $0.00 Strike: $2.78 | $0.00 |
DisclosureSEC source: 0001415889-24-015138 · form4-06032024_080652.xml · derivative · entry 4 Cavanaugh Sarah · CIK 0001709113 · SVP OF CORP AFFAIRS & ADMIN. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,750 shares Expires 2029-06-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: As of June 19, 2023, the option is fully vested. Read SEC document |
| May 30, 2024 Filed Jun 3, 2024 20:04 UTC |
Cavanaugh SarahSVP OF CORP AFFAIRS & ADMIN.
|
SaleCommon Stock | 20,853 | $33.73 | $703,334.15 |
DisclosureSEC source: 0001415889-24-015138 · form4-06032024_080652.xml · nonDerivative · entry 3 Cavanaugh Sarah · CIK 0001709113 · SVP OF CORP AFFAIRS & ADMIN. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,860 F2 · kind: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.465 to $34.06 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. F2 · shares: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.465 to $34.06 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.465 to $34.06 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| May 30, 2024 Filed Jun 3, 2024 20:04 UTC |
Cavanaugh SarahSVP OF CORP AFFAIRS & ADMIN.
|
Exercise / conversionCommon Stock | 10,103 | $9.02 | $91,093.70 |
DisclosureSEC source: 0001415889-24-015138 · form4-06032024_080652.xml · nonDerivative · entry 2 Cavanaugh Sarah · CIK 0001709113 · SVP OF CORP AFFAIRS & ADMIN. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,713 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 30, 2024 Filed Jun 3, 2024 20:04 UTC |
Cavanaugh SarahSVP OF CORP AFFAIRS & ADMIN.
|
Exercise / conversionCommon Stock | 10,750 | $2.78 | $29,885.00 |
DisclosureSEC source: 0001415889-24-015138 · form4-06032024_080652.xml · nonDerivative · entry 1 Cavanaugh Sarah · CIK 0001709113 · SVP OF CORP AFFAIRS & ADMIN. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,610 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 576 shares of common stock acquired under the Celldex Therapeutics, Inc. 2004 Employee Stock Purchase Plan. Read SEC document |
| May 30, 2024 Filed Jun 3, 2024 20:04 UTC |
Crowley ElizabethSR. VP & CPDO
|
Exercise / conversionIncentive Stock Option (Right to Buy) · Derivative | 8,500 | $0.00 Strike: $9.02 | $0.00 |
DisclosureSEC source: 0001415889-24-015137 · form4-06032024_080604.xml · derivative · entry 5 Crowley Elizabeth · CIK 0001681854 · SR. VP & CPDO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 8,500 shares Expires 2028-06-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: As of June 13, 2022, the option is fully vested. Read SEC document |
| May 30, 2024 Filed Jun 3, 2024 20:04 UTC |
Crowley ElizabethSR. VP & CPDO
|
Exercise / conversionIncentive Stock Option (Right to Buy) · Derivative | 34,445 | $0.00 Strike: $2.78 | $0.00 |
DisclosureSEC source: 0001415889-24-015137 · form4-06032024_080604.xml · derivative · entry 4 Crowley Elizabeth · CIK 0001681854 · SR. VP & CPDO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 34,445 shares Expires 2029-06-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: As of June 19, 2023, the option is fully vested. Read SEC document |
| May 30, 2024 Filed Jun 3, 2024 20:04 UTC |
Crowley ElizabethSR. VP & CPDO
|
SaleCommon Stock | 38,597 | $33.64 | $1,298,383.78 |
DisclosureSEC source: 0001415889-24-015137 · form4-06032024_080604.xml · nonDerivative · entry 3 Crowley Elizabeth · CIK 0001681854 · SR. VP & CPDO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,074 F1 · kind: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.39 to $33.8934 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. F1 · shares: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.39 to $33.8934 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.39 to $33.8934 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| May 30, 2024 Filed Jun 3, 2024 20:04 UTC |
Crowley ElizabethSR. VP & CPDO
|
Exercise / conversionCommon Stock | 8,500 | $9.02 | $76,640.25 |
DisclosureSEC source: 0001415889-24-015137 · form4-06032024_080604.xml · nonDerivative · entry 2 Crowley Elizabeth · CIK 0001681854 · SR. VP & CPDO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,671 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 30, 2024 Filed Jun 3, 2024 20:04 UTC |
Crowley ElizabethSR. VP & CPDO
|
Exercise / conversionCommon Stock | 34,445 | $2.78 | $95,757.10 |
DisclosureSEC source: 0001415889-24-015137 · form4-06032024_080604.xml · nonDerivative · entry 1 Crowley Elizabeth · CIK 0001681854 · SR. VP & CPDO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,171 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 21:05 UTC |
Jimenez Freddy A.SVP & GENERAL COUNSEL
|
Exercise / conversionIncentive Stock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $2.78 | $0.00 |
DisclosureSEC source: 0001415889-24-003891 · form4-02152024_090240.xml · derivative · entry 4 Jimenez Freddy A. · CIK 0001838114 · SVP & GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2029-06-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: As of June 19, 2023, the option is fully vested. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 21:05 UTC |
Jimenez Freddy A.SVP & GENERAL COUNSEL
|
Exercise / conversionIncentive Stock Option (Right to Buy) · Derivative | 4,166 | $0.00 Strike: $9.02 | $0.00 |
DisclosureSEC source: 0001415889-24-003891 · form4-02152024_090240.xml · derivative · entry 3 Jimenez Freddy A. · CIK 0001838114 · SVP & GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,166 shares Expires 2028-06-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On February 8, 2019, Celldex Therapeutics, Inc. effected a 1-for-15 reverse stock split of its common stock (the "Reverse Stock Split"). This option was previously reported as covering 62,500 shares at an exercise price of $0.6011 per share, but has been adjusted to reflect the Reverse Stock Split. F1 · shares: On February 8, 2019, Celldex Therapeutics, Inc. effected a 1-for-15 reverse stock split of its common stock (the "Reverse Stock Split"). This option was previously reported as covering 62,500 shares at an exercise price of $0.6011 per share, but has been adjusted to reflect the Reverse Stock Split. F3 · derivative.exercise_date: As of June 13, 2022, the option is fully vested. F1 · derivative.underlying_shares: On February 8, 2019, Celldex Therapeutics, Inc. effected a 1-for-15 reverse stock split of its common stock (the "Reverse Stock Split"). This option was previously reported as covering 62,500 shares at an exercise price of $0.6011 per share, but has been adjusted to reflect the Reverse Stock Split. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 21:05 UTC |
Jimenez Freddy A.SVP & GENERAL COUNSEL
|
Exercise / conversionCommon Stock | 20,000 | $2.78 | $55,600.00 |
DisclosureSEC source: 0001415889-24-003891 · form4-02152024_090240.xml · nonDerivative · entry 2 Jimenez Freddy A. · CIK 0001838114 · SVP & GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,924 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 21:05 UTC |
Jimenez Freddy A.SVP & GENERAL COUNSEL
|
Exercise / conversionCommon Stock | 4,166 | $9.02 | $37,562.74 |
DisclosureSEC source: 0001415889-24-003891 · form4-02152024_090240.xml · nonDerivative · entry 1 Jimenez Freddy A. · CIK 0001838114 · SVP & GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,924 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On February 8, 2019, Celldex Therapeutics, Inc. effected a 1-for-15 reverse stock split of its common stock (the "Reverse Stock Split"). This option was previously reported as covering 62,500 shares at an exercise price of $0.6011 per share, but has been adjusted to reflect the Reverse Stock Split. F1 · price: On February 8, 2019, Celldex Therapeutics, Inc. effected a 1-for-15 reverse stock split of its common stock (the "Reverse Stock Split"). This option was previously reported as covering 62,500 shares at an exercise price of $0.6011 per share, but has been adjusted to reflect the Reverse Stock Split. F2 · balance_after: Includes 1,328 shares of common stock acquired under the Celldex Therapeutics, Inc. 2004 Employee Stock Purchase Plan. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:05 UTC |
Martin Samuel BatesSVP AND CFO
|
Exercise / conversionIncentive Stock Option (Right to Buy) · Derivative | 10,750 | $0.00 Strike: $2.78 | $0.00 |
DisclosureSEC source: 0001415889-24-000592 · form4-01042024_090138.xml · derivative · entry 2 Martin Samuel Bates · CIK 0001709024 · SVP AND CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,750 shares Expires 2029-06-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: As of June 19, 2023, the option is fully vested. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:05 UTC |
Martin Samuel BatesSVP AND CFO
|
Exercise / conversionCommon Stock | 10,750 | $2.78 | $29,885.00 |
DisclosureSEC source: 0001415889-24-000592 · form4-01042024_090138.xml · nonDerivative · entry 1 Martin Samuel Bates · CIK 0001709024 · SVP AND CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,128 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 15, 2023 Filed Jun 20, 2023 20:21 UTC |
Young Diane C.SVP, CHIEF MEDICAL OFFICER
|
GrantIncentive Stock Option (right to buy) · Derivative | 80,000 | $0.00 Strike: $36.87 | $0.00 |
DisclosureSEC source: 0001415889-23-010049 · form4-06202023_080658.xml · derivative · entry 1 Young Diane C. · CIK 0001648010 · SVP, CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2033-06-15 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: 25% vest on June 15, 2024 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
| June 15, 2023 Filed Jun 20, 2023 20:19 UTC |
Wright Richard M.SR. VP & CCO
|
GrantIncentive Stock Option (right to buy) · Derivative | 45,000 | $0.00 Strike: $36.87 | $0.00 |
DisclosureSEC source: 0001415889-23-010048 · form4-06202023_080633.xml · derivative · entry 1 Wright Richard M. · CIK 0001646423 · SR. VP & CCO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2033-06-15 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: 25% vest on June 15, 2024 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
| June 15, 2023 Filed Jun 20, 2023 20:18 UTC |
PEPIN RONALDSR. VP & CBO
|
GrantIncentive Stock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $36.87 | $0.00 |
DisclosureSEC source: 0001415889-23-010047 · form4-06202023_080630.xml · derivative · entry 1 PEPIN RONALD · CIK 0001214504 · SR. VP & CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2033-06-15 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: 25% vest on June 15, 2024 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
| June 15, 2023 Filed Jun 20, 2023 20:17 UTC |
Martin Samuel BatesSVP AND CFO
|
GrantIncentive Stock Option (right to buy) · Derivative | 80,000 | $0.00 Strike: $36.87 | $0.00 |
DisclosureSEC source: 0001415889-23-010046 · form4-06202023_080654.xml · derivative · entry 1 Martin Samuel Bates · CIK 0001709024 · SVP AND CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2033-06-15 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: 25% vest on June 15, 2024 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
| June 15, 2023 Filed Jun 20, 2023 20:17 UTC |
Jimenez Freddy A.SVP & GENERAL COUNSEL
|
GrantIncentive Stock Option (right to buy) · Derivative | 74,000 | $0.00 Strike: $36.87 | $0.00 |
DisclosureSEC source: 0001415889-23-010045 · form4-06202023_080605.xml · derivative · entry 1 Jimenez Freddy A. · CIK 0001838114 · SVP & GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,000 Underlying: Common Stock · 74,000 shares Expires 2033-06-15 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: 25% vest on June 15, 2024 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
| June 15, 2023 Filed Jun 20, 2023 20:16 UTC |
Heath-Chiozzi MargoSVP OF REGULATORY AFFAIRS
|
GrantIncentive Stock Option (right to buy) · Derivative | 80,000 | $0.00 Strike: $36.87 | $0.00 |
DisclosureSEC source: 0001415889-23-010044 · form4-06202023_080633.xml · derivative · entry 1 Heath-Chiozzi Margo · CIK 0001718112 · SVP OF REGULATORY AFFAIRS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2033-06-15 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: 25% vest on June 15, 2024 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
| June 15, 2023 Filed Jun 20, 2023 20:16 UTC |
Crowley ElizabethSR. VP &CPDO
|
GrantIncentive Stock Option (right to buy) · Derivative | 80,000 | $0.00 Strike: $36.87 | $0.00 |
DisclosureSEC source: 0001415889-23-010043 · form4-06202023_080649.xml · derivative · entry 1 Crowley Elizabeth · CIK 0001681854 · SR. VP &CPDO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2033-06-15 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: 25% vest on June 15, 2024 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
| June 15, 2023 Filed Jun 20, 2023 20:15 UTC |
Cavanaugh SarahSVP OF CORP AFFAIRS & ADMIN.
|
GrantIncentive Stock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $36.87 | $0.00 |
DisclosureSEC source: 0001415889-23-010042 · form4-06202023_080654.xml · derivative · entry 1 Cavanaugh Sarah · CIK 0001709113 · SVP OF CORP AFFAIRS & ADMIN. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2033-06-15 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: 25% vest on June 15, 2024 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
| June 15, 2023 Filed Jun 20, 2023 20:14 UTC |
KELER TIBOREXECUTIVE VP & CSO
|
GrantIncentive Stock Option (right to buy) · Derivative | 92,000 | $0.00 Strike: $36.87 | $0.00 |
DisclosureSEC source: 0001415889-23-010041 · form4-06202023_080658.xml · derivative · entry 1 KELER TIBOR · CIK 0001429931 · EXECUTIVE VP & CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,000 Underlying: Common Stock · 92,000 shares Expires 2033-06-15 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: 25% vest on June 15, 2024 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
| June 15, 2023 Filed Jun 20, 2023 20:13 UTC |
Marucci Anthony SDirector · PRESIDENT & CEO
|
GrantIncentive Stock Option (right to buy) · Derivative | 250,000 | $0.00 Strike: $36.87 | $0.00 |
DisclosureSEC source: 0001415889-23-010039 · form4-06202023_080657.xml · derivative · entry 1 Marucci Anthony S · CIK 0001429933 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2033-06-15 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: 25% vest on June 15, 2024 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
| June 15, 2023 Filed Jun 20, 2023 20:11 UTC |
Brownlie Keith LDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 11,300 | $0.00 Strike: $36.87 | $0.00 |
DisclosureSEC source: 0001415889-23-010038 · form4-06202023_080621.xml · derivative · entry 1 Brownlie Keith L · CIK 0001518575 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,300 Underlying: Common Stock · 11,300 shares Expires 2033-06-15 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. Read SEC document |
| June 15, 2023 Filed Jun 20, 2023 20:10 UTC |
PENNER HARRY JRDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 11,300 | $0.00 Strike: $36.87 | $0.00 |
DisclosureSEC source: 0001415889-23-010037 · form4-06202023_080641.xml · derivative · entry 1 PENNER HARRY JR · CIK 0001131148 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,300 Underlying: Common Stock · 11,300 shares Expires 2033-06-15 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. Read SEC document |
| June 15, 2023 Filed Jun 20, 2023 20:10 UTC |
NEIL GARRY ARTHURDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 11,300 | $0.00 Strike: $36.87 | $0.00 |
DisclosureSEC source: 0001415889-23-010036 · form4-06202023_080604.xml · derivative · entry 1 NEIL GARRY ARTHUR · CIK 0001586785 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,300 Underlying: Common Stock · 11,300 shares Expires 2033-06-15 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. Read SEC document |
| June 15, 2023 Filed Jun 20, 2023 20:09 UTC |
MARINO JAMES JDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 11,300 | $0.00 Strike: $36.87 | $0.00 |
DisclosureSEC source: 0001415889-23-010035 · form4-06202023_080610.xml · derivative · entry 1 MARINO JAMES J · CIK 0001198578 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,300 Underlying: Common Stock · 11,300 shares Expires 2033-06-15 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. Read SEC document |
| June 15, 2023 Filed Jun 20, 2023 20:08 UTC |
CONRAD HERBERT JDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 11,300 | $0.00 Strike: $36.87 | $0.00 |
DisclosureSEC source: 0001415889-23-010034 · form4-06202023_080626.xml · derivative · entry 1 CONRAD HERBERT J · CIK 0001218815 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,300 Underlying: Common Stock · 11,300 shares Expires 2033-06-15 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. Read SEC document |
| June 15, 2023 Filed Jun 20, 2023 20:07 UTC |
Cohen CherylDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 11,300 | $0.00 Strike: $36.87 | $0.00 |
DisclosureSEC source: 0001415889-23-010033 · form4-06202023_080641.xml · derivative · entry 1 Cohen Cheryl · CIK 0001529371 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,300 Underlying: Common Stock · 11,300 shares Expires 2033-06-15 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. Read SEC document |
| June 15, 2023 Filed Jun 20, 2023 20:07 UTC |
Shoos Karen L.Director
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 11,300 | $0.00 Strike: $36.87 | $0.00 |
DisclosureSEC source: 0001415889-23-010032 · form4-06202023_080655.xml · derivative · entry 1 Shoos Karen L. · CIK 0001255681 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,300 Underlying: Common Stock · 11,300 shares Expires 2033-06-15 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 21:30 UTC |
Jain RitaDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 17,100 | $0.00 Strike: $42.34 | $0.00 |
DisclosureSEC source: 0001493152-23-005663 · ownership.xml · derivative · entry 1 Jain Rita · CIK 0001707797 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,100 Underlying: Common Stock · 17,100 shares Expires 2033-02-16 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: One third vests on the first, second and third anniversaries of the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.